Euronext Paris
Every company in the roster listed on Euronext Paris.
Every company in the roster listed on Euronext Paris.
8 of 8 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
AB ScienceAB · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | MasitinibPhase 3 · Alzheimer's DiseaseReliable signal | Dec 2027Masitinib · Phase 3 | — | $10MJun 2026 | ~5.6 qtrswith a later raise | ~$20M |
AdociaADOC · Euronext Paris | 1 asset: 1 Ph 3 | THDB0206Phase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
GenfitGNFT · Euronext Paris | 2 assets: 1 approved, 1 Ph 2 | EzurpimtrostatPhase 1/2 · Cholangiocarcinoma with KRAS Mutation | 17 Dec 2026Elafibranor · Phase 3 | — | $119MDec 2025 | Ended Apr 2026 | $117M |
Innate PharmaIPH · Euronext Paris | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | MonalizumabPhase 3 · Non-Small Cell Lung CancerPartial signal | Apr 2028IPH4502 · Phase 1 | — | — | — | — |
IpsenIPN · Euronext Paris | 3 assets: 3 approved | Approved assets only | 17 Dec 2026Elafibranor · Phase 3 | — | — | — | — |
MedincellMEDCL · Euronext Paris | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
OSE ImmunotherapeuticsOSE · Euronext Paris | 2 assets: 1 Ph 3, 1 Ph 2 | OSE2101Phase 3 · Non-Small Cell Lung CancerPartial signal | 1 May 2028OSE2101 · Phase 3 | — | — | — | — |
TransgeneTNG · Euronext Paris | 1 asset: 1 Ph 2 | T101Phase 2 · Chronic Hepatitis B | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.